Annual General Meeting

2022 AGM Schedule

The AGM is a closed meeting for GlycoNet Network Investigators and HQP only, and Non-Disclosure Agreements are required to attend. The AGM starts Monday, May 9 with project presentations, followed by a closed poster session in the evening. The meeting continues on Tuesday, May 10 with project presentations and professional development workshops. The Canadian Glycomics Symposium opens in the morning on Wednesday, May 11.

For more information about the Canadian Glycomics Symposium, which is open to all members of the scientific community and the public, check out the Symposium page.

* Schedule as of May 6, 2022 and subject to change.

06:00 – 09:00 PM

AGM Registration Opens Max Bell Central Foyer
7:00 – 8:50 AMBreakfast – Vistas Dining Room
7:00 – 8:50 AMAGM Registration – Max Bell Central Foyer
8:50 – 9:00 AMWelcome Remarks Max Bell Auditorium

9:00 – 10:30 AM

 

Project Presentations Max Bell Auditorium

Development of next-generation glyco-caged drugs to treat enteric inflammatory diseases in humans and livestock
Project Leader: Harry Brumer, UBC

Modulatory and therapeutic roles of gangliosides in neurodegeneration and neuroinflammation
Project Leader: Simonetta Sipione, UAlberta

Development of a glycobiology therapy to mitigate the progression of Duchenne muscular dystrophy
Project Leader: Sachiko Sato, ULaval

10:30 – 10:50 AMBreak – Max Bell Central Foyer
10:50 AM – 12:05 PM

Project Presentations Max Bell Auditorium

Towards universal blood through enzymatic red blood cell modification
Project Leader: Stephen Withers, UBC

Regulation of inflammatory response to bacterial infections by human neuraminidase enzymes
Project Leader: Christopher Cairo, UAlberta

Selective GBA2 inhibitors and their evaluation in cell models of Batten disease
Project Leader: David Vocadlo, SFU

Taming cytokine storms with a P- and E-selectin antagonist to treat coronavirus acute respiratory distress syndrome (ARDS)
Project Leader: Yvan Guindon, IRCM

12:05 AM – 1:15 PMLunch Vistas Dining Room
1:00 – 4:00 PMProfessional Headshots (Sign-up at Registration) – Kinnear Centre 208
1:15 – 2:30 PM

Project Presentations Max Bell Auditorium

Lead discovery for inhibitors of lipopolysaccharide biosynthesis
Project Leader: Eric Brown, McMaster

Innovative therapies for neurological lysosomal storage disorders
Project Leader: Alexey Pshezhetsky, CHU St-Justine

Clinical trial for Montbretin A diabetics
Project Leader: Stephen Withers, UBC

2:30 – 2:50 PMBreak – Max Bell Central Foyer
2:50 – 4:05 PM

Project Presentations Max Bell Auditorium

Modulating CD33 splicing as a protective therapeutic strategy in Alzheimer’s disease
Project Leader: Matthew Macauley, UAlberta

Mitigation of necrotic enteritis by improving the integrity of intestinal mucin through small molecules and stress management
Project Leaders: Wesley Zandberg, UBC & Wade Abbott, AAFC

Identification of targets of glucocerebrosidase activators and optimization of PET imaging agents
Project Leader: David Vocadlo, SFU

4:30 – 5:45 PMTrainee Mixer – Max Bell 252
6:00 – 6:15 PMRemarks from GlycoNet Board Chair Kinnear Centre 101-105
6:15 – 9:00 PMPoster Session & Buffet Dinner Kinnear Centre 101-105
7:00 – 9:00 AMBreakfast Vistas Dining Room
8:30 – 10:00 AM

HQP Workshop: Drug Development Bench to Clinic

Max Bell 252

9:00 – 10:30 AM

Project Presentations – Max Bell Auditorium

Systematic characterization of Siglecs and their glycan ligands in cancer
Project Leader: Matthew Macauley, UAlberta

Inhibitors of antibody fucosylation: commercialization-enabling studies
Project Leader: Robert Britton, SFU

Bringing a candidate Haemophilus influenzae serotype A vaccine through late pre-clinical development into a Phase 1, randomized placebo-controlled, observer-blind trial
Project Leader: Brian Ward, McGill

Phase I/IIa clinical trial for the treatment of Tay-Sachs and Sandhoff disease using AAV9-Hex gene therapy
Project Leader: Jagdeep Walia, Queen’s

10:20 – 11:50 AM

HQP Workshop: Writing Effective EDI Statements

Max Bell 252

10:30 – 10:50 AMBreak – Max Bell Central Foyer
10:50 AM – 12:05 PM

Project Presentations – Max Bell Auditorium

Anti-exopolysaccharide therapies to improve eradication of early Pseudomonas aeruginosa infection in CF
Project Leader: Valerie Waters, SickKids

A platform for the rapid synthesis of nucleoside analogues
Project Leader: Robert Britton, SFU

The EARLY study: Economic evAluation of a novel pRostate cancer gLYcan-based diagnostic tool
Project Leader: Annalijn Conklin, UBC

12:05 PM – 1:15 PMLunch – Vistas Dining Room
1:00 – 2:30 PM

HQP Workshop: Building Your Confidence as a Scientist

Max Bell 252

1:15 – 2:30 PM

Legacy Workshop Max Bell Auditorium

2:30 – 2:50 PMBreak – Max Bell Central Foyer
2:30 – 5:00 PM

Professional Headshots (Sign-up Required) Kinnear Centre 208

2:50 – 4:30 PM

HQP Workshop: Career Panel: I Graduated, Now What?

Max Bell 252

2:50 – 4:30 PM

Legacy Workshop Max Bell Auditorium

4:30 – 8:00 PM

Free Time

8:00 – 11:00 PM

AGM Mixer 

Rose & Crown  
202 Banff Ave

7:00 – 9:00 AM Breakfast Vistas Dining Room
9:00 AM Departure for AGM-Only Attendees
Scroll to Top